Evidence map›Paper›PMID 37320934›Full record

ArticleEuropean journal of cancer (Oxford, England : 1990)2023

Tolerability of immune checkpoint inhibitors in patients with cancer and pre-existing multiple sclerosis.

L Chavaz, D Guyon, A Boespflug, C Cauquil, J M Michot

Abstract readLetterComment
PubMed Publisher
In one paragraph

Article in European journal of cancer (Oxford, England : 1990), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 3 pooled it
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 3 syntheses or guidelines pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Impact of Immune Checkpoint Inhibitors on the Course of Multiple Sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2024
    Article
  6. Review
  7. Article
  8. Clinical outcomes after use of checkpoint inhibitor immunotherapies in people with multiple sclerosis.Multiple sclerosis journal - experimental, translational and clinical
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

L ChavazGustave Roussy, Université Paris-Saclay, Département des Innovations Thérapeutiques et Essais Précoces, Villejuif, France.
D GuyonGustave Roussy, Université Paris-Saclay, Département d'Oncologie Médicale et des Soins de Support, Villejuif, France.
A BoespflugGustave Roussy Institute, Department of oncology, Villejuif, France.
C CauquilAssistance Publique - Hôpitaux de Paris, Hôpital Bicêtre, Service de Neurologie Adulte, Le Kremlin Bicêtre, France.
J M MichotGustave Roussy, Université Paris-Saclay, Département des Innovations Thérapeutiques et Essais Précoces, Villejuif, France; Université Paris-Saclay, Gustave Roussy, Unité Mixte de Recherche 1170, Villejuif, France. Electronic address: jean-marie.michot@gustaveroussy.fr.
Institut Gustave Roussy · FRAssistance Publique – Hôpitaux de Paris · FRUniversité Paris-Saclay · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic Agents, ImmunologicalMultiple SclerosisNeoplasmsHumansImmune Checkpoint InhibitorsAntineoplastic Agents, ImmunologicalImmune Checkpoint Inhibitors

Identifiers

PMID37320934
OpenAlexW4380766285

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.